Hill, Andrew GrahamFindlay, MichaelBurge, MatthewJackson, ChristopherGarcia Alfonso, PilarSamuel, LeslieGanju, VinodKarthaus, MeinolfAmatu, AlessioJeffrey, MarkDi Bartolomeo, MariaBridgewater, JohnCoveler, AndrewHidalgo, ManuelKapp, AmySufan, RoxannaMcCall, BruceHanley, WilliamPenuel, EliciaPirzkall, AndreaTabernero, Josep2019-03-052019-03-052018-05Hill, A G, Findlay, M, Burge, M, Jackson, C, Garcia Alfonso, P, Samuel, L, Ganju, V, Karthaus, M, Amatu, A, Jeffrey, M, Di Bartolomeo, M, Bridgewater, J, Coveler, A, Hidalgo, M, Kapp, A, Sufan, R, McCall, B, Hanley, W, Penuel, E, Pirzkall, A & Tabernero, J 2018, 'Phase II study of the dual EGFR/HER3 inhibitor duligotuzumab (MEHD7945A) vs. cetuximab in combination with FOLFIRI in RAS wild-type metastatic colorectal cancer', Clinical Cancer Research, vol. 24, no. 10, pp. 2276-2284. https://doi.org/10.1158/1078-0432.CCR-17-06461078-0432ORCID: /0000-0002-8402-8670/work/50559793http://hdl.handle.net/2164/11999Acknowledgments The authors wish many thanks to all of the patients and the investigators who participated in this study. Writing assistance was provided by Genentech, Inc. This work was supported by Genentech, Inc. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.92313146engSDG 3 - Good Health and Well-beingR MedicineRJournal article10.1158/1078-0432.CCR-17-06462410